Fiocruz and AstraZeneca make a commitment for API acquisition in 2022

8 November 2021

Brazil’s Fiocruz has signed a joint declaration of commitment with UK pharma major AstraZeneca (LSE: AZN) for the acquisition of Active Pharmaceutical Ingredient (API) with the goal of producing 60 million doses of the COVID-19 vaccine (recombinant) in order to make up the deliveries of the Foundation for 2022.

The commitment signed by the institutions aims to guarantee wide availability of vaccine doses for the first semester. With the guarantee of the imported ingredient, Fiocruz will be able to deliver, through the Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz), 120 million doses between January and June next year, of which 60 million with the national API and 60 million with the new agreement.

The guaranteed availability of this amount will allow the Ministry of Health (MS), depending on the epidemiological situation of COVID-19 in Brazil until then, to establish different protocols of vaccination and to use the doses to implement booster vaccination whenever it is necessary.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK